TI
GEVA

Turner Investments’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Turner Investments’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-209,744
Closed -$8.81M – 725
2013
Q2 		$8.81M Buy
+209,744
New +$9.56M 0.12% 233

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Turner Investments's GEVA Position: Q3 2013 in Review

Turner Investments sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q3 2013, closing a stake of 209,744 shares — an estimated $8.81M sold.

Turner Investments first reported a position in GEVA in Q2 2013 and held it in 1 quarter. The position peaked at $8.81M in Q2 2013. 95 funds tracked by Wall St. Rank hold GEVA as of Q3 2013.

  • Turner Investments reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q3 2013 after selling out during the quarter.
  • Turner Investments sold 209,744 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q3 2013, an estimated $8.81M.
  • Turner Investments first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 1 quarter.
  • Turner Investments's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $8.81M in Q2 2013.
  • 95 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q3 2013.

Based on Turner Investments's 13F filing for Q3 2013, filed 12 Nov 2013.